alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 332.30 Labeling of antiflatulent drug products. ( a ) *Statement of identity.* The labeling of the product contains the established name of the drug, if any, and identifies the product as an “antiflatulent,” “antigas,” or “antiflatulent (antigas).”
( b ) *Indications.* The labeling of the product states, under the heading “Indications,” one or more of the phrases listed in this paragraph (b), as appropriate. Other truthful and nonmisleading statements, describing only the indications for use that have been established and listed in this paragraph (b), may also be used, as provided in § 330.1(c)(2) of this chapter, subject to the provisions of section 502 of the Federal Food, Drug, and Cosmetic Act (the act) relating to misbranding and the prohibition in section 301(d) of the act against the introduction or delivery for introduction into interstate commerce of unapproved new drugs in violation of section 505(a) of the act. ( 1 ) (Select one of the following: “Alleviates or Relieves”) “the symptoms referred to as gas.”
( 2 ) (Select one of the following: “Alleviates” or “Relieves”) (select one or more of the following: “bloating,” “pressure,” “fullness,” or “stuffed feeling”) “commonly referred to as gas.”
( c ) *Exemption from the general accidental overdose warning.* The labeling for antiflatulent drug products containing simethicone identified in § 332.10 and antacid/antiflatulent combination drug products provided for in § 332.15, containing the active ingredients identified in § 331.11(a), (b), and (d) through (m) of this chapter are exempt from the requirement in § 330.1(g) of this chapter that the labeling bear the general warning statement “In case of accidental overdose, seek professional assistance or contact a poison control center immediately.” The labeling must continue to bear the first part of the general warning in § 330.1(g) of this chapter, which states, “Keep this and all drugs out of the reach of children.”
[39 FR 19877, June 4, 1974, as amended at 40 FR 11719, Mar. 13, 1975; 51 FR 16266, May 1, 1986; 51 FR 27763, Aug. 1, 1986; 52 FR 7830, Mar. 13, 1987; 61 FR 8838, Mar. 5, 1996]
# L_2009091EN.01003102.xml

| 3.4.2009 | EN | Official Journal of the European Union | L 91/31 |
| --- | --- | --- | --- |

3.4.2009

EN

Official Journal of the European Union

L 91/31

---

Corrigendum to Council Directive 94/45/EC of 22 September 1994 on the establishment of a European Works Council or a procedure in Community-scale undertakings and Community-scale groups of undertakings for the purposes of informing and consulting employees

(
  Official Journal of the European Communities L 254 of 30 September 1994
  )

On page 68, Article 6(2), introductory wording:

for:

‘2.   Without prejudice to the autonomy of the parties, the agreement referred to in paragraph 1 between the central management and the special negotiating body shall determine:’,

read:

‘2.   Without prejudice to the autonomy of the parties, the agreement referred to in paragraph 1 and effected in writing between the central management and the special negotiating body shall determine:’.

---
§ 352.50 Principal display panel of all sunscreen drug products. In addition to the statement of identity required in § 352.52, the following labeling statements shall be prominently placed on the principal display panel: ( a ) *For products that do not satisfy the water resistant or very water resistant sunscreen product testing procedures in § 352.76* — ( 1 ) *For products with SPF values up to 30.* “SPF (insert tested SPF value of the product up to 30).”
( 2 ) *For products with SPF values over 30.* “SPF 30” (select one of the following: “plus” or “ + ”). Any statement accompanying the marketed product that states a specific SPF value above 30 or similar language indicating a person can stay in the sun more than 30 times longer than without sunscreen will cause the product to be misbranded under section 502 of the Federal Food, Drug, and Cosmetic Act (the act).
( b ) *For products that satisfy the water resistant sunscreen product testing procedures in § 352.76 .* ( 1 ) (Select one of the following: “Water,” “Water/Sweat,” or “Water/Perspiration”) “Resistant.”
( 2 ) “SPF (insert SPF value of the product, as stated in paragraph (a)(1) or (a)(2) of this section, after it has been tested using the water resistant sunscreen product testing procedures in § 352.76).”
( c ) *For products that satisfy the very water resistant sunscreen product testing procedures in § 352.76 .* ( 1 ) “Very” (select one of the following: “Water,” “Water/Sweat,” or “Water/Perspiration”) “Resistant.”
( 2 ) “SPF (insert SPF value of the product, as stated in paragraph (a)(1) or (a)(2) of this section, after it has been tested using the very water resistant sunscreen product testing procedures in § 352.76).”
#### § 520.1802 Piperazine-carbon disulfide complex oral dosage forms.
**Exhibit 31.1**

​

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

​

I, Dale Foster, certify that:

​

1.I have reviewed this annual report on Form 10-K/A of Wayside Technology Group, Inc; and

​
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

​

Date:  April 29, 2020

​

| ​                              | ​ |
|--------------------------------------|---------|
| /s/ Dale Foster                      | ​ |
| Dale Foster                          | ​ |
| Chief Executive Officer and Director | ​ |

​

​

----
---

---

**Exhibit
  8**

|LIST OF
      SUBSIDIARIES
|--------------------------
|                          
|NAME OF
      SUBSIDIARY  
|                          
|                          
|                          

|Active                                                                    
|--------------------------------------------------------------------------
|                                                                          
|Encre
      Consumables B.V.                                              
|NUR America, Inc.                                                         
|NUR Asia Pacific (Hong
      Kong) Ltd.                                   
|NUR DO Brazil Ltda.                                                       
|NUR Europe S.A.                                                           
|NUR Hungary Trading
      and Software Licensing Limited Liability Company
|NUR Macroprinters
      (Shanghai) Ltd.                                   
|NUR Media Solutions
      S.A.                                            
|Salsa Digital Printers
      Ltd.                                         
|NUR Japan Ltd.                                                            
|NUR Pro Engineering
      Ltd.                                            
|                                                                          

---

---
Exhibit 23.1

March 12,
2009

Mr. Kevin
Herrmann
Chief Financial Officer
Ballantyne of Omaha, Inc.
4350 McKinley Street
Omaha NE 68112

Subject:
WRITTEN CONSENT TO REFERENCE GIFFORD FONG ASSOCIATES VALUATION IN FORM 10-K FILING OF BALLANTYNE OF OMAHA, INC FOR THE PERIOD ENDED DECEMBER 31, 2008.

Dear
Mr. Herrmann:

We
hereby consent to the inclusion on Form 10-K of Ballantyne of Omaha, Inc. for the period ended December 31, 2008 to make references to our report
relating to the valuation of the auction-rate securities of Ballantyne of Omaha, Inc. as of December 31, 2008, and to references to our firm's name therein.

Sincerely,

Gifford
Fong Associates

/s/
H. Clifford Fong
H. Clifford Fong
Senior Vice President

---



QuickLinks
§ 338.50 Labeling of nighttime sleep-aid drug products. ( a ) *Statement of identity.* The labeling of the product contains the established name of the drug, if any, and identifies the product as a “nighttime sleep-aid.”
( b ) *Indications.* The labeling of the product states, under the heading “Indications,” one or more of the phrases listed in this paragraph. Other truthful and nonmisleading statements, describing only the indications for use that have been established and listed in this paragraph (b), may also be used, as provided in § 330.1(c)(2) of this chapter, subject to the provisions of section 502 of the act relating to misbranding and the prohibition in section 301(d) of the act against the introduction or delivery for introduction into interstate commerce of unapproved new drugs in violation of section 505(a) of the act. ( 1 ) (“Helps you” or “Reduces time to”) “fall asleep if you have difficulty falling asleep.”
( 2 ) “For relief of occasional sleeplessness.”
( 3 ) “Helps to reduce difficulty falling asleep.”
( c ) *Warnings.* The labeling of the product contains the following warnings under the heading “Warnings”: ( 1 ) “Do not give to children under 12 years of age.”
( 2 ) “If sleeplessness persists continuously for more than 2 weeks, consult your doctor. Insomnia may be a symptom of serious underlying medical illness.”
( 3 ) “Do not take this product, unless directed by a doctor, if you have a breathing problem such as emphysema or chronic bronchitis, or if you have glaucoma or difficulty in urination due to enlargement of the prostate gland.”
( 4 ) “Avoid alcoholic beverages while taking this product. Do not take this product if you are taking sedatives or tranquilizers, without first consulting your doctor.”
( 5 ) “Do not use [bullet][1] with any other product containing diphenhydramine, even one used on skin”.
( d ) *Directions.* The labeling of the product contains the following information under the heading “Directions”: ( 1 ) *For products containing diphenhydramine hydrochloride identified in § 338.10(a) .* Adults and children 12 years of age and over: Oral dosage is 50 milligrams at bedtime if needed, or as directed by a doctor.
( 2 ) *For products containing diphenhydramine citrate identified in § 338.10(b) .* Adults and children 12 years of age and over: Oral dosage is 76 milligrams at bedtime if needed, or as directed by a doctor.
( e ) The word “physician” may be substituted for the word “doctor” in any of the labeling statements in this section.
[54 FR 6826, Feb. 14, 1989, as amended at 59 FR 16983, Apr. 11, 1994; 67 FR 72559, Dec. 6, 2002] Footnotes -
338.50
[1] See § 201.66(b)(4) of this chapter for definition of bullet symbol.
### Artificial recharge through a well tapping basalt aquifers at the Dalles, Oregon

By: B. L. FoxworthyCharles T. Bryant

                            https://doi.org/10.3133/wsp1594E

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plate:  **Plate 1**                            (pdf)
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
#### Shirley Woods et al. *v.*John Wodecki

Inglis, O. J., Baldwin, O’Sullivan, Wynne and Daly, Js.

Argued May 5

decided June 7, 1955

*Sebastian J. Russo,*for the appellants (plaintiffs).

*Robert Y. Pelgrift,*for the appellee (defendant).

Per Curiam.

There is no error.
Attachment 1 1

The relief provided by Exemption No. 10690H is limited to the air carri ers listed below:

Airlines for America Alaska Airlines American Airlines Atlas Air, Inc. Hawaiian Airlines, Inc. JetBlue Airways Corp. Southwest Airlines Co. United Airlines, Inc Air Canada (Associate Member)

National Air Carrier Association Air Transport International Allegiant Air Atlas Air, Inc. Eastern Airlines Everts Air Cargo Kalitta Air Lyndon Air Cargo Miami Air International National Airlines National Air Cargo Northern Air Cargo Omni Air International Southern Air Spirit Airlines Sun Country Airlines USA Jet Airlines Western Global

Regional Airline Association Air Wisconsin Airlines Corp. Cape Air CommutAir Compass Airlines Empire Air Endeavor Airlines Envoy ExpressJet Airlines GoJet Airlines Grand Canyon Airlines/Scenic Great Lakes Aviation

1 Attachment amended May 26, 2017.Hawaii Island Air Horizon Air Jazz Air Mesa Airlines New England Airlines Piedmont Airlines PSA Airways RAVN Alaska Republic Airlines Seaborne Airlines Shuttle America Silver Airways SkyWest Airlines Surf Air Trans States Airlines

Additional Air Carriers 2 Delta Air Lines, Inc. Peninsula Airways Virgin America, Inc. Vision Airlines, Inc.

2 Additional air carriers petitioned for exemption through the following FAA Docket Numbers: Delta Air Lines,FAA-2013-0034; Peninsula Airways, FAA-2017-0196; Virgin America, FAA-2013-0034; Vision Airlines, FAA2016-8158
#### § 133.3 Definitions.

(a) *Milk* means the lacteal secretion, practically free from colostrum, obtained by the complete milking of one or more healthy cows, which may be clarified and may be adjusted by separating part of the fat therefrom; concentrated milk, reconstituted milk, and dry whole milk. Water, in a sufficient quantity to reconstitute concentrated and dry forms, may be added.

(b) *Nonfat milk* means skim milk, concentrated skim milk, reconstituted skim milk, and nonfat dry milk. Water, in a sufficient quantity to reconstitute concentrated and dry forms, may be added.

(c) *Cream* means cream, reconstituted cream, dry cream, and plastic cream. Water, in a sufficient quantity to reconstitute concentrated and dry forms, may be added.

(d) *Pasteurized* when used to describe a dairy ingredient means that every particle of such ingredient shall have been heated in properly operated equipment to one of the temperatures specified in the table of this paragraph and held continuously at or above that temperature for the specified time (or other time/temperature relationship which has been demonstrated to be equivalent thereto in microbial destruction):

| Temperature | Time |
| --- | --- |
| 145 °F1 | 30 min. |
| 161 °F1 | 15 s. |
| 191 °F | 1 s. |
| 204 °F | 0.05 s. |
| 212 °F | 0.01 s. |
| | |
| --- | --- |
| 1 If the dairy ingredient has a fat content of 10 percent or more, the specified temperature shall be increased by 5 °F. | |

(e) *Ultrapasteurized* when used to describe a dairy ingredient means that such ingredient shall have been thermally processed at or above 280 °F for at least 2 seconds.

[[48 FR 2742](https://www.federalregister.gov/citation/48-FR-2742), Jan. 21, 1983; [48 FR 11426](https://www.federalregister.gov/citation/48-FR-11426), Mar. 18, 1983]
<PAGE>   1
                        CONSENT OF INDEPENDENT AUDITORS

The Board of Directors
Vixel Corporation

We consent to the use of our report dated May 1, 1997 relating to the balance
sheet of Arcxel Technologies, Inc. as of December 31, 1996 and the related
statements of operations, stockholders' equity and cash flows for the period
from June 18, 1996 (inception) to December 31, 1996 incorporated by reference
in the Registration Statement on Form S-8 of Vixel Corporation.

KPMG LLP

Orange County California
September 28, 1999
§ 26.64 Transitional arrangements. The parties agree to implement the transitional commitments on confidence building as specified in subparts A and B of this part. ( a ) The parties agree that each sectoral transitional arrangement shall specify a time period for completion.
( b ) The parties may amend any transitional arrangement by mutual agreement.
( c ) Passage from the transitional phase to the operational phase shall proceed as specified in subparts A and B of this part, unless either party documents that the conditions provided in such subpart for a successful transition are not met.
#### § 520.763 Dithiazanine oral dosage forms.
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 05-6731

UNITED STATES OF AMERICA,

Plaintiff - Appellee,

versus

JOHN LENWOOD WRIGHT, a/k/a June Bug,

Defendant - Appellant.

Appeal from the United States District Court for the Eastern

District of Virginia, at Alexandria. Claude M. Hilton, District

Judge. (CR-02-539; CA-04-1370-1)

Submitted: September 14, 2005 Decided: November 16, 2005

Before WILLIAMS, MICHAEL, and GREGORY, Circuit Judges.

Dismissed by unpublished per curiam opinion.

John Lenwood Wright, Appellant Pro Se. Kimberly Riley Pedersen,

OFFICE OF THE UNITED STATES ATTORNEY, Alexandria, Virginia, for

Appellee.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
- 2 -

PER CURIAM:

John Lenwood Wright seeks to appeal the district court’s

order dismissing as untimely his 28 U.S.C. § 2255 (2000) motion.

An appeal may not be taken from the final order in a § 2255

proceeding unless a circuit justice or judge issues a certificate

of appealability. 28 U.S.C. § 2253(c)(1) (2000). A certificate of

appealability will not issue absent “a substantial showing of the

denial of a constitutional right.” 28 U.S.C. § 2253(c)(2) (2000).

A prisoner satisfies this standard by demonstrating that reasonable

jurists would find that the district court’s assessment of his

constitutional claims is debatable and that any dispositive

procedural rulings by the district court are also debatable or

wrong. See Miller-El v. Cockrell, 537 U.S. 322, 336 (2003);

Slack v. McDaniel, 529 U.S. 473, 484 (2000); Rose v. Lee, 252 F.3d

676, 683 (4th Cir. 2001). We have independently reviewed the

record and conclude that Wright has not made the requisite showing.

Accordingly, we deny a certificate of appealability and dismiss the

appeal. We dispense with oral argument because the facts and legal

contentions are adequately presented in the materials before the

court and argument would not aid the decisional process. 

DISMISSED
38828.

#### ECHOLS v. THE STATE.

Decided April 11, 1961

Rehearing denied April 19, 1961.

James Echols, *pro se.*

*Preston M. Almand, Solicitor,*contra.

Frankum, Judge.

In the instant case there is no certification of . the bill of exceptions as true as required by *Code Ann.*§ 6-806. The only certificate is one requiring the clerk of the trial court to copy; certify and transmit certain parts of the ■record specified to this court. There is no question before this cofirt for decision, and, therefore, the purported writ of error must be dismissed. *Beasley v. Georgia Power Co.,*207 Ga. 188 (60 S. E. 2d 363); *Studges v. State,*86 Ga. App. 760 (72 S. E. 2d 505).

*Writ of error dismissed.*

*Tcnvnsend, P. J., and Jordan,-J., concur.*
Injection Well Plugging Plan for FutureGen Alliance

Permit Number: IL

- 137

- 6A -0001 (Well #1) Page D1of 3



### ATTACHMENT D : INJECTION WELL PLUGGING PLAN

Facility Name: FutureGen 2.0 Morgan County CO 2 

### Storage Site

IL

- 137

- 6A

- 0001 ( W ell #1)

Facility Contacts: Kenneth Humphreys , Chief Executive Officer,

FutureGen Industrial Alliance, Inc., Morgan County Office,
73 Central Park Plaza East, Jacksonville, IL 62650, 217

- 243

- 8215

Location of Injection Well: Morgan County, IL; 26−16N− 9W; 39.80 111 oN and 90.074 91 oW

The FutureGen Alliance shall comply with the reporting and notification provisions in

40 CFR 146.92.

Immediately Prior to Well Plugging: Per the requirements at 40 CFR 146.92, The FutureGen Alliance must:

1. Flush each injection well with a buffer fluid;

2. Determine the bottomhole reservoir pressure using methods and procedures identified in

Attachment C

– Testing and Monitoring Plan; and

3. Demonstrate external mechanical integrity using methods and procedures identified in

Attachment C

– Testing and Monitorin g Plan.

Information on Plugs:

Cementing to Plug and

Abandon Data Plug #1 Plug #2 Plug #3 Plug #4 Plug #5 Plug #6 Plug #7

Diamete r of Boring in Which Plug Will B e Placed (in) 7 7 7 7 7 7

Depth to Bottom of Tubing

or Drill Pipe (MD) (ft) 6

, 004 or 7,004 (a) 3,900 3,100 1,800 1,500 700

Sacks of Cement to B e Used (each plug) (sks) 45 1 or
665 (a) 149 0 53 0 124

Slurry Volume to B e Pumped (ft 3 ) 505 or
745 (a) 167 271 63 167 146

Slurry Weight (lb/ft 3 ) 15.8 15.8 8.6 15.6 8.6 15.6

Top of Plug (MD) (ft) 3

, 900 3

, 100 1

, 800 1

, 500 700 0

Bottom of Plug (MD) (ft) 6

, 004 or 7,004 (a) 3

, 900 3

, 100 1

, 800 1

, 500 700

Type of Cement or Other

Material EverCrete EverCrete 6% Gel Class A 6% Gel Class A

Method of Emplacement (e.g., balance method,
retainer method, or two

plug method) Balance Method

(a) This value applies to injection wells completed with a 2,500 ft lateral. MD = measured depth.Injection Well Plugging Plan for FutureGen Alliance

Permit Number: IL

- 137

- 6A -0001 (Well #1) Page D2of 3 

### Figure 1. Diagram of Injection Well after Plugging and Abandonment (geology and depths

shown in t his diagram are based on site-specific characterization data obtained from the FutureGen 2.0 Stratigraphic Well).Injection Well Plugging Plan for FutureGen Alliance

Permit Number: IL

- 137

- 6A -0001 (Well #1) Page D3of 3